NASH is a liver disease that affects millions of Americans. Researchers expect it to become the leading cause of liver transplants in the US within the next few years.But now, Intercept Pharmaceuticals is preparing to launch the first-ever treatment for NASH. The treatment still needs to be approved by US regulators.
Now 18 years into Intercept's story, Pruzanski is still at the helm as CEO and still based on the west side of Manhattan. And he's still arguing with skeptical investors and doctors about the potential market for his liver disease drug. The disease has been a hot topic in biotech for the past few years. As the biotech industry witnessed high-profile NASH failures last year, Intercept stood alone in succeeding.
The same drug, called Ocaliva, has already been approved to treat a rare liver disease at a price of about $84,000 a year, before rebates and discounts. For NASH, the company has applied for a distinct brand name that can carry a separate price. Pruzanski acknowledged the uncertainty surrounding not just Intercept's drug but the disease as a viable market. The investor debate ramped up after Intercept announced initial positive results a year ago, he said.
Canada Canada Latest News, Canada Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Business Insider Intelligence - Business InsiderThe article was interesting, but the title... 🤦♂️🙅♂️ Divorce is never a good thing, it’s never a positive and should not be celebrated. That means one or both parties for whatever reason failed the other. sometimes they don;t even need any promotion at all ! Liberation , freedom is all they need !!
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »